ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1666421
This article is part of the Research TopicInnovations in Immunometabolic Treatment and Controlled Release Systems for Bone and Joint DisordersView all 14 articles
Modulatory Efficacy of Bone Metabolism and Safety of Denosumab versus Zoledronic Acid in the Treatment of Bone and Joint Osteoporosis in Elderly Men
Provisionally accepted
- 1Sheyang County People’s Hospital, Yancheng, China
- 2Shanghai Jiao Tong University School of Medicine, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aimed to compare the clinical efficacy and safety of denosumab versus zoledronic acid (ZA) in the treatment of osteoporosis in elderly male patients, with the goal of optimizing therapeutic strategies for this population. Methods: A retrospective analysis was conducted on 89 elderly male osteoporosis patients treated at Sheyang County People's Hospital from March 2023 to March 2024. Patients were allocated to two treatment arms based on the treatment regimen they received: the denosumab group (n=49) and the ZA group (n=40). Adverse drug reactions (e.g., myalgia, flu-like symptoms, and back pain) were recorded, and changes in bone metabolism markers and bone mineral density (BMD) at the lumbar spine (L1-L4), femoral neck, and total hip were evaluated after one year of treatment. Results: After one year of treatment, BMD of lumbar spine significantly increased in both groups (P<0.05), with the denosumab group showing a greater improvement (0.41±0.68 vs. 0.14±0.86, P=0.037). In contrast, the ZA group demonstrated superior efficacy in BMD of femoral neck (P=0.011) and total hip (P=0.029). Adverse reactions occurred in 15 patients: 2 in the denosumab group (muscle pain) and 13 in the ZA group (10 flu-like symptoms, 2 muscle pain, and 1 back pain). The incidence of flu-like symptoms was significantly higher in the ZA group (32.5% vs. 0%, P < 0.001). Conclusion: Denosumab demonstrated superior efficacy in reducing fracture risk at the lumbar spine, while ZA showed greater protective effects at the hip. Although both agents significantly improved bone metabolic parameters, denosumab exhibited a more favorable safety profile in clinical application.
Keywords: Osteoporosis, Elderly men, Denosumab, Zoledronic Acid, bone metabolism
Received: 15 Jul 2025; Accepted: 14 Oct 2025.
Copyright: © 2025 He, Mao, Gong, Zhu, Xiang, Wang and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jing He, 904812087@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.